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Cowden disease, also known as multiple hamartoma
syndrome, is a rare disease inherited in an autosomal
dominant pattern, which confers a high risk of develop-
ing breast and thyroid carcinomas. Mutations in PTEN,
a tumor suppressor gene located on chromosome 10q23,
have been identi¢ed in patients with Cowden disease. In
this work, the direct sequencing of all coding regions of
the PTEN gene led us to the identi¢cation of N48K, a
new germline PTEN missense mutation, in a patient
su¡ering from Cowden disease. The genetic analysis of
200 chromosomes from healthy individuals revealed
that the variant was not common in our population.
Moreover, by functional analysis we found that the abil-
ity of PTEN N48K mutant protein to inhibit the activa-
tion of the proto-oncogene PKB/Akt was impaired,
supporting the involvement of N48K mutation in Cow-
den disease. Loss of heterozygosity using three microsa-
tellites (D10S215, D10S541, and D10S564) and the
complete sequence analysis of PTEN exons in breast
and endometrial tumor samples from the same patient
were also carried out in an attempt to identify addi-
tional PTEN somatic mutations. The lack of loss of het-
erozygosity or additional mutations in tumor samples
suggests that abnormalities of the regulatory regions of
the PTEN gene or haplo-insu⁄ciency might occur in
tumors from Cowden disease patients. Key words: Cowden
disease/functional analysis/genetic analysis/loss of heterozyg-
osity/N48K/PTEN. J Invest Dermatol 121:1356 ^1359, 2003
C
owden disease (CD; MIM 158350), also known as
multiple hamartoma syndrome, is a rare disease in-
herited in an autosomal dominant pattern. CD in-
cludes trichilemmomas (benign tumors of the hair
follicle infundibulum), acral keratoses, papilloma-
tous lesions, and mucosal lesions (Starink, 1984; Starink et al,
1986; Hanssen and Fryns, 1995; Longy and Lacombe, 1996). In ad-
dition, a¡ected women have a high risk of developing ¢brocystic
disease and carcinomas of the breast; goiter, adenomas, follicular
cell carcinomas of the thyroid gland, and polyps of the digestive
tract are also found in a¡ected individuals (Brownstein et al, 1979;
Starink et al, 1986; Schrager et al, 1998). These manifestations can
be associated with several neurologic disorders such as dysplastic
gangliocytoma of the cerebellum (LhermitteDuclos disease),
megalencephaly (Padberg et al, 1991), and other neurologic signs
such as tremor, ataxia, epilepsy, and mental retardation (reviewed
by Longy and Lacombe, 1996).
Germline mutations on the tumor suppressor gene PTEN
(phosphatase and tensin homolog deleted on chromosome 10)
(MIM #601728), also called MMAC1 (mutated in multiple ad-
vanced cancers) or TEP1 (tumor growth factor b regulated and
epithelial cell enriched phosphatase), have been established as the
cause of CD. Moreover, somatic PTEN mutations have been
found in a large number of sporadic tumors, predominantly in
endometrial carcinomas and glioblastomas (reviewed in Bonneau
and Longy, 2000).
PTEN protein is a phosphatase with enzymatic activity to-
wards both protein substrates and the lipid second messenger
phosphatidylinositol-3,4,5-triphosphate (Myers et al, 1997; Maeha-
ma and Dixon, 1998; Tamura et al, 1998). PTEN regulates distinct
signal transduction pathways including the PKB/Akt cell survival
and the integrin-triggered signaling pathways (reviewed in Cant-
ley and Neel, 1999; Maehama and Dixon, 1999;Tamura et al, 1999;
Di Cristofano and Pandol¢, 2000). In tumors and cell lines, an
inverse correlation exists between the presence of a functional li-
pid phosphatase PTEN enzyme and the activity of the PKB/Akt
proto-oncogene (Haas-Kogan et al, 1998; Stambolic et al, 1998;
Wu et al, 1998; Dahia et al, 1999; Ermoian et al, 2002). The PTEN
protein structure consists of a 179-residue N-terminal domain
(residues 7^185) and a 166-residue C-terminal domain (residues
186^351). The N-terminal domain is a phosphatase domain that
is similar to that of protein tyrosine phosphatases but has an en-
larged active site important for the accommodation of the phos-
phoinositide substrate. The C-terminal domain is a C2 domain
that binds phospholipid membranes in vitro (Lee et al, 1999).
A recent review of germline mutations of human PTEN gene
(Bonneau and Longy, 2000) described 82 di¡erent mutations and
two gross deletions located along the whole gene, with the ex-
ception of exon 9. Interestingly, a great number of the mutations
were found in exon 5 (n¼ 35, 31.5%), which encodes for the
phosphatase core motif.
In this study, we have sequenced all the PTEN coding region
from peripheral blood leukocytes of a woman diagnosed with
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CD. The identi¢cation of a new missense mutation in exon 2 led
us to perform a functional analysis of the PTENmutated protein,
as well as other genetic analysis on breast and endometrial tumors
from the patient, to shed light on the pathogenicity of the muta-
tion.
MATERIALS AND METHODS
All experiments and the informed patient consent protocols are correct
from the ethical point of view and previously reviewed by the Ethical
Committee of the Faculty of Medicine of the University of Santiago de
Compostela. The work was conducted according to the Spanish law in-
cluding adherence to the Heisinki Principles.
Phenotypic description We studied a 38-y-old woman with CD. The
patient presents the clinical features of the disease, such as thyroid a¡ection
(multinodular goiter), skin lesions (trichilemmomas, oral lesions such as
verrucous lesions of the palate, cobblestone-like papules of the gingiva,
palmoplantar keratoses), invasive and intraductal breast carcinoma,
gastrointestinal alterations (one adenomatous polyp of the colon), and also
endometrial carcinoma and ovarian cyst. Other features are obesity,
hyrsutism, and ¢bromialgia.
The patient’s mother was diagnosed with a squamous cell carcinoma
in situ (CIN III) of the uterine cervix at 70 y of age. The patient has no
brothers or sisters, and in the mother’s family there are patients with
goiter and breast cancer (unfortunately, it was not possible to obtain
samples from them), although the patient studied here has the stronger
symptoms in the family.
DNA extraction DNA was extracted from 5 ml of peripheral blood
using a standard proteinase K/phenol/chloroform procedure. The samples
were incubated in 50 mM Tris-HCl, 150 mM NaCl, 100 mM Na2
ethylenediamine tetraacetic acid, sodium dodecyl sulfate 1.25%, and 0.3
mg per ml proteinase K. DNA was precipitated with absolute ethanol
after two extractions with phenol:chloroform:isoamyl alcohol (25:24:1)
and chloroform:isoamyl alcohol (24:1).
Tumor tissues from breast and endometrial carcinomas of the patient
were studied. The breast tumor was an invasive ductal carcinoma of grade
I (Nottingham modi¢cation of the Bloom-Richardson system) with
extensive intraductal carcinoma of cribriform type. Metastatic lymph
nodes were not found. Tumor cells were positive for estrogen (clone GF11,
dilution 1:10, Novocastra, Newcastle upon Tyne, UK) and progesterone
receptors (clone 1a6, dilution 1:5, Novocastra). The endometrial tumor was
a well-di¡erentiated endometrioid carcinoma with squamous metaplasia
(adenoacanthoma). DNA was obtained from para⁄n-embedded tissue.
Brie£y, to dissolve the para⁄n the tissue section was rapidly washed with
xylene and centrifuged and the pellet was washed three times with ethanol
at decreasing concentrations. After that it was then resuspended in 50 mL of
digestion bu¡er and incubated at 371C overnight.
Mutation screening Each of the nine exons of the PTEN gene was
ampli¢ed under standard PCR conditions using 100 ng of genomic DNA
obtained from a blood sample or 2 mL of DNA solution obtained from
breast and from endometrial tumor extractions. Ampli¢cations were
made in 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 200 mM of each
dNTP, 10 pmol of each primer, and 1.25 units Taq polymerase (Invitrogen
Life Technologies, Carlsbad, CA), in a ¢nal volume of 25 mL. Reactions
were performed in a PerkinElmer Cetus 2400 thermocycler, consisting of
an initial denaturation step at 951C for 5 min followed by 35 cycles of 30 s
at 941C, 45 s at the appropriate annealing temperature (501C for exons 2, 3,
4, 5, 6; 601C for exons 1, 7, 8, 9), and 1 min at 721C. The PCR product was
puri¢ed using ExoSapI (Amersham Pharmacia Biotech, Uppsala, Sweden)
previous to the sequence reaction. Sequence reactions were carried out
using the DYEnamic ET Terminator Cycle Sequencing Kit (Amersham
Pharmacia Biotech). The sequencing reaction was 30 cycles at 951C for
20 s, 551C for 20 s, and 601C for 1 min. Sequences were run in a Mega-
bace capillary sequencer (Amersham Pharmacia Biotech) using forward
and reverse primers. (Primer sequences are available upon request.)
Electrophoresis conditions were as follows: sample injection voltage 2 s;
sample injection time 40 s; run voltage 7 kV; run time 100 min.
Analysis of control individuals 200 chromosomes from healthy
individuals of our population were genotyped by single strand
conformation polymorphism (SSCP) analysis at the variant N48K. Exon
2 PCR products were diluted 1:10 in loading bu¡er (deionized formamide
and blue dextran), heated at 951C for 5 min, and then cooled on ice.
SSCP analysis was performed in a semiautomatic electrophoretic system
(PhastSystem, Amersham Pharmacia Biotech) using PhastGel (T¼ 20%
polyacrylamide gels) and Native bu¡er strips. One microliter of the
denatured product was applied to the cathodic end.The running conditions
during the separation step were 400 V, 5.0 mA, 1.0 W at 151C for a total of
600 V h. A prerun with 400 V, 5.0 mA, 1.0 W at 151C for a total of 20 V h
was added. After electrophoresis PhastGels were silver stained.
Comparative sequence analysis between species and related phos-
phatases The PTEN phosphatase domain, containing the Asn48 residue,
was compared by amino acid sequence alignment between Homo sapiens,
Xenopus laevis, Rattus norvegicus, Drosophila melanogaster, Caenorhabditis
elegans, Dictyostelium discoideum, and Arabidopsis thaliana (Genebank accession
numbers NM_000314, AF144732, AF017185, AF144232, AF126286, AF483827,
and AJ490172, respectively). A comparison of human PTEN with TPTE
(AF00718) and TPIP (NM_130785), two human related phosphatases, was
also carried out.
Loss of heterozygosity (LOH) analysis For LOH analysis three
dinucleotide microsatellite markers (D10S215, D10S541, and D10S564) and
the exon 2 of the PTEN gene that contained the mutation N48K were
considered. Genomic DNA corresponding to DNA extracted from
endometrial and breast tumor, as well as the blood sample of the patient,
was subjected to PCR ampli¢cation with the previously described
conditions and using an annealing temperature of 551C for all three
microsatellites. For microsatellite LOH analysis PCR products were
detected in an automated £uorescent system: 5 mL of loading bu¡er (5 mg
per ml dextran blue/formamide) was added to 1 mL of each PCR product
and combined with internal lane standards. The samples were heat
denatured at 941C for 4 min before being loaded onto a gel (ReproGel
High Resolution, Amersham Pharmacia Biotech) with a ¢nal concen-
tration of 8% (wt/vol) acrylamide/bisacrylamide monomers and 1TBE
(Tris-Borate-EDTA). Electrophoresis was carried out at 1500 V, 30 W, and
60 mA for 2 h on the Automatic Laser Fluorescent DNA sequencer
(Amersham Pharmacia Biotech).
LOH at exon 2 was studied by sequence comparison of tumor (breast
and endometrial) with the blood sample from the patient.
Cell culture, transfections, and plasmids The U87MG cell line was
grown in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10%
heat-inactivated fetal bovine serum. Cells were transfected with the
indicated plasmids using FuGENE 6 (Roche Diagnostics, Basal,
Switzerland) following the recommendations of the manufacturer. The
pRK5 PTEN wild-type, pSG5 HA-PKB, and pEF-BOS-Ras V12 have
been described previously ( Jimenez et al, 1998; Torres and Pulido, 2001).
The pRK5 PTEN N48K and pRK5 PTEN G129E mutations were
obtained by PCR oligonucleotide site-directed mutagenesis, and the
mutations were con¢rmed by DNA sequencing.
Analysis of PKB activation Transfected U87MG cells were lyzed in
lysis bu¡er (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1% Nonidet P-40;
1mM phenylmethylsulfonyl £uoride; 1mg per ml aprotinin; 2 mMNa3VO4;
20 mM Na4P2O7). The activation of HA-PKB was assessed by immunoblot
using the antiphospho-active-PKB/Akt (Ser473) antibody (Cell Signalling
Technologies Beverly, MA), following immunoprecipitation of HA-PKB
from the lysates with the anti-HA monoclonal antibody 12CA5. The
anti-PKB/Akt and anti-PTEN antibodies were from Santa Cruz
Biotechnologies (Santa Cruz, CA) and Cascade Bioscience, (Winchester,
MA) respectively. Immunoblot and stripping of the membranes were
performed as described previously (Torres and Pulido, 2001).
RESULTS
Mutation analysis We sequenced all coding regions of the
PTEN gene from a blood sample as well as from breast and
endometrial tumor samples of a patient with CD. A
heterozygous variant in exon 2 of the gene, which was
con¢rmed in a second independent PCR and sequence reaction,
was found at the germline (Fig 1) and was also present in both
tumor samples. The variant was a single nucleotide substitution
at nucleotide 144, and originates a change at codon 48 of the
PTEN protein. The amino acid asparagine (AAC) at codon 48,
which is polar and uncharged, turns to lysine (AAA), which is a
positively charged amino acid, originating the missense mutation
N48K. No other change was found at tumor level.
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Analysis of control individuals To discard the variant N48K
as a common polymorphism, 200 chromosomes from healthy
individuals of our population were genotyped by SSCP analysis.
The absence of N48K in the control population suggests that the
variant is not a common polymorphism and points to a disease-
associated mutation.
Comparative sequence analysis As the mutation N48K is
located at the N-terminal catalytic domain of the PTEN
protein, in the vicinity of the enzyme active center, we carried
out a comparative amino acid sequence analysis between
di¡erent species to know the conservation grade of the Asn48
residue. As shown in Fig 2(A), Asn48 is present in all of the
species, suggesting an important role for this residue in PTEN
function. In addition, Asn48 is also conserved in the two PTEN-
related phosphatases,TPTE and TPIP (Fig 2B).
LOH Biopsy specimens from an invasive ductal carcinoma of
grade I and well-di¡erentiated endometrioid carcinoma with
squamous metaplasia (adenoacanthoma) were evaluated for LOH
at microsatellite markers D10S215, D10S541, and D10S564, and at
the PTEN nucleotide 144. All the three microsatellites were
heterozygous in the blood sample of the patient as well as in
both tumor samples (breast and endometrial), showing no LOH.
None of the tumor types was hemizygous for the mutation at
nucleotide 144.
Analysis of PKB/Akt activation To test the implications of
the N48K mutation on PTEN function, the capacity of a PTEN
N48K mutant protein to inhibit the activation of the proto-
oncogene PKB/Akt in the U87MG PTEN-null cell line was
tested (Fig 3). As shown, inhibition of PKB/Akt activation by
the PTEN N48K mutation was impaired (Fig 3, lanes 3, 7), as
observed for the lipid phosphatase inactive G129E mutation (Fig
3, lanes 4, 8) (Myers et al, 1998). The impairment of PTEN
function in the mutant proteins was observed both in normal
cell growth conditions (Fig 3, lanes 1^4) and on stimulation of
PKB/Akt by expression of the constitutively active form of Ras,
RasV12 (Fig 3, lanes 5^8).
DISCUSSION
In this work the study of a female diagnosed with CD led us to
the identi¢cation of a new missense mutation (N48K) in exon 2
of the PTEN gene. An extensive bibliographic and database
search for PTEN mutations showed that N48K is a variant not
previously reported.
As the implication of each missense mutation in the develop-
ment of a disease has to be con¢rmed, additional analyses were
performed to establish the pathogenicity of N48K in CD. First,
a genotype analysis of 200 chromosomes from healthy indivi-
duals was performed by SSCP analysis of exon 2; it was found
that the variant was not common in our population: none of the
chromosomes analyzed presented the change N48K. Second, the
capacity of a PTEN N48K mutant protein to inhibit the activa-
tion of the proto-oncogene PKB/Akt was tested. The ability of
the PTEN N48K mutation to inhibit PKB/Akt activation was
impaired, as shown for the lipid phosphatase inactive G129E mu-
tation (Fig 3), which has been associated with CD (Liaw et al,
1997; Myers et al, 1998). Thus, the N48K mutation renders a
PTEN enzyme inactive, probably by altering the conformation
of the nearby catalytic site and/or by making the accessibility to
the phosphatidylinositol-3,4,5-triphosphate substrate di⁄cult.
The recent observation of germline mutations of the PTEN
gene in patients with CD provides strong evidence that PTEN
functions as a tumor suppressor gene in this disease and related
inherited disorders (Nelen et al, 1996; Liaw et al, 1997; Steck et al,
1997). It is well known that inactivation of a tumor suppressor
gene generally involves independent inactivation of both alleles,
usually by a point mutation of one allele and deletion of the other
wild-type allele (Knudson et al, 1975). Nevertheless, in our analy-
sis, and using markers D10S215, D10S541, and D10S564, we de-
tected the presence of both PTEN alleles, as well as the variant
N48K in heterozygous status, in breast and endometrial tumors
Figure1. Nucleotide sequence of a fragment of exon 2 of the PTEN
gene containing the variant (arrow). (A) Wild-type sequence. (B) Het-
erozygous mutation N48K.
Figure 2. PTEN protein inter and intra speci-
¢c homologies. (A) PTEN phosphatase domain
amino acid sequence homology across species. Se-
quence homologies are underlined. Aspargine at
codon 48 is indicated with a verticle rectangle. In
C. elegans an insertion is indicated with a line and
the amino acid letter. (B) Phosphatase domain
amino acid sequence homology between human
PTEN and human phosphatases TPTE and TPIP.
Codon 48 is indicated with an arrow.
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from the patient under study. Moreover, the complete sequence
analysis of PTEN exons in breast and endometrial tumor samples
revealed the absence of a second point mutation. This ¢nding is
similar to that reported by Cairns et al (1998) who in a recent
study of PTEN mutations and deletions in primary bladder can-
cers demonstrated a low frequency of biallelic inactivation, sug-
gesting other mechanisms of PTEN inactivation such as
hypermethylation or even the involvement of another gene.
Other recent works also support the implication of abnormal
methylation in the PTEN promoter region in the tumorigenesis
process (Chi et al, 1998;Whang et al, 1998; Salvesen et al, 2001).
In summary, we report here the identi¢cation of N48K, a new
germline PTEN missense mutation, in a patient su¡ering from
CD. By both genetic and functional analysis we con¢rm the
pathogenicity of the mutation in CD. As we did not ¢nd a sec-
ond mutation at tumor level, we speculate that abnormalities of
the regulatory regions of the PTEN gene not targeted by our
study, such as the promotor region, transcriptional silencing
(e.g., via methylation), or even haplo-insu⁄ciency might occur
in cases where a coding mutation of this gene is seen in the ab-
sence of LOH at the wild-type allele.
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